Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Trial Profile

Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Buparlisib (Primary) ; Paclitaxel
  • Indications Carcinoma; Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms BERIL-1
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 28 Feb 2018 Results of biomarker analysis published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 24 Jun 2017 This trial has been discontinued in Ireland (End date:2017-03-30) as per European Clinical Trials Database record.
    • 15 Jun 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top